Combined conventional transarterial chemoembolization with Mitomycin and percutaneous ablation for unresectable hepatocellular carcinoma

被引:5
作者
Yamada, Ricardo [1 ]
Bassaco, Beatriz [1 ]
Bracewell, Stephen [1 ]
Volin, Samuel [1 ]
Collins, Heather [1 ]
Hannegan, Christopher [1 ]
Guimarares, Marcelo [1 ]
机构
[1] Med Univ South Carolina, Dept Radiol, Div Vasc & Intervent Radiol, 25 Courtenay Dr,MAS 226, Charleston, SC 29425 USA
关键词
Hepatocellular carcinoma (HCC); transarterial embolization; percutaneous ablation; RADIOFREQUENCY THERMAL ABLATION; COMBINATION; THERAPY; METAANALYSIS; EMULSIONS; OIL;
D O I
10.21037/jgo.2019.01.07
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Conventional transarterial chemoembolization (cTACE) has been the standard treatment for intermediate stage hepatocellular carcinoma (HCC). For early stage HCC, percutaneous ablation is a curative option. There is growing evidence to support combined therapy to improve tumor response and overall survival (OS) in patients with unresectable HCC. The goal of this study is to retrospectively review a single institution patient population who underwent the combined approach to determine its efficacy and safety, and possible predictive factors for OS and tumor response. Methods: Retrospective analysis identified all patients that underwent c-TACE with Mitomycin followed by percutaneous ablation from 2011 to 2016 at our institution. Efficacy was assessed by OS, time to progression (TTP), and tumor response according to mRECIST criteria. Initial imaging was obtained 1 month after each treatment and after complete response was achieved, every 3 months for 2 years. Percentage of Lipiodol uptake was determined at 30-day follow-up with contrasted abdominal CT. Safety was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Multiple linear regressions were conducted to predict OS and number of progression-free survival days based on potential predictive factors. Results: A total of 50 patients were identified. At 1-month follow-up, objective response (CR + PR) was achieved in 44 patients (88%). The median OS was 26.6 months and median TIT was 9.7 months (n=50). There was no statistically significant difference in median OS between patients with different lesion size (P=0.95), BCLC stage (P=0.84) or Lipiodol uptake (P=0.36). Higher albumin/bilirubin ratio was significantly correlated with improved OS (P=0.024). Conclusions: Combined c-TACE and PTA is a safe and effective approach for patients with unresectable HCC. Elevated albumin/bilirubin ratio was a predictor for improved OS.
引用
收藏
页码:298 / 303
页数:6
相关论文
共 21 条
  • [1] Quality Improvement Guidelines for Transhepatic Arterial Chemoembolization, Embolization, and Chemotherapeutic Infusion for Hepatic Malignancy
    Brown, Daniel B.
    Nikolic, Boris
    Covey, Anne M.
    Nutting, Charles W.
    Saad, Wael E. A.
    Salem, Riad
    Sofocleous, Constantinos T.
    Sze, Daniel Y.
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2012, 23 (03) : 287 - 294
  • [2] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [3] Transarterial chemoembolization for unresectable hepatocellular carcinoma:: Meta-analysis of randomized controlled trials
    Cammà, C
    Schepis, F
    Orlando, A
    Albanese, M
    Shahied, L
    Trevisani, F
    Andreone, P
    Craxì, A
    Cottone, M
    [J]. RADIOLOGY, 2002, 224 (01) : 47 - 54
  • [4] Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis
    Chen, Qi-Wen
    Ying, Hai-Feng
    Gao, Song
    Shen, Ye-Hua
    Meng, Zhi-Qiang
    Chen, Hao
    Chen, Zhen
    Teng, Wen-Jing
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2016, 40 (03) : 309 - 314
  • [5] Quantification of tumor uptake of iodized oils and emulsions of iodized oils: Experimental study
    deBaere, T
    Zhang, XW
    Aubert, B
    Harry, G
    Lagrange, C
    Ropers, J
    Dufaux, J
    Lumbroso, J
    Rougier, P
    Ducreux, M
    Roche, A
    [J]. RADIOLOGY, 1996, 201 (03) : 731 - 735
  • [6] Dhanasekaran R, 2013, J CANC THER, V4, P493, DOI DOI 10.4236/JET.2013.42060
  • [7] Society of Interventional Radiology Position Statement on Percutaneous Radiofrequency Ablation for the Treatment of Liver Tumors
    Gervais, Debra A.
    Goldberg, S. Nahum
    Brown, Daniel B.
    Soulen, Michael C.
    Millward, Steven F.
    Rajan, Dheeraj K.
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2009, 20 (01) : 3 - 8
  • [8] Radiofrequency ablation of hepatic tumors: Increased tumor destruction with adjuvant liposomal doxorubicin therapy
    Goldberg, SN
    Kamel, IR
    Kruskal, JB
    Reynolds, K
    Monsky, WL
    Stuart, KE
    Ahmed, M
    Raptopoulos, V
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2002, 179 (01) : 93 - 101
  • [9] Ethiodized oil emulsions in hepatic microcirculation: In vivo microscopy in animal models
    Kan, ZX
    Wright, K
    Wallace, S
    [J]. ACADEMIC RADIOLOGY, 1997, 4 (04) : 275 - 282
  • [10] Comparative Efficacy of Interventional Therapies for Early-stage Hepatocellular Carcinoma A PRISMA-compliant Systematic Review and Network Meta-analysis
    Lan, Tian
    Chang, Lei
    Rahmathullah, M. N.
    Wu, Long
    Yuan, Yu-Feng
    [J]. MEDICINE, 2016, 95 (15)